MX375638B - Proceso para la fabricación de medicamentos. - Google Patents

Proceso para la fabricación de medicamentos.

Info

Publication number
MX375638B
MX375638B MX2016013162A MX2016013162A MX375638B MX 375638 B MX375638 B MX 375638B MX 2016013162 A MX2016013162 A MX 2016013162A MX 2016013162 A MX2016013162 A MX 2016013162A MX 375638 B MX375638 B MX 375638B
Authority
MX
Mexico
Prior art keywords
manufacture
medicines
viiia
sup
compound
Prior art date
Application number
MX2016013162A
Other languages
English (en)
Spanish (es)
Other versions
MX2016013162A (es
Inventor
Alexandra Chestakova
Chunbo Sha
Wei Gu
Haiming Zhang
Hans Iding
Jianqian Zhang
Jinguang Lin
Jing Li
Patrik Meier
Jeffrey Stults
Xin Linghu
Youchu Wang
Tao Zhang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2016013162A publication Critical patent/MX2016013162A/es
Publication of MX375638B publication Critical patent/MX375638B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
MX2016013162A 2014-04-09 2015-04-08 Proceso para la fabricación de medicamentos. MX375638B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014075011 2014-04-09
PCT/CN2015/076083 WO2015154674A1 (en) 2014-04-09 2015-04-08 Process for the manufacturing of medicaments

Publications (2)

Publication Number Publication Date
MX2016013162A MX2016013162A (es) 2017-04-27
MX375638B true MX375638B (es) 2025-03-06

Family

ID=54287327

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013162A MX375638B (es) 2014-04-09 2015-04-08 Proceso para la fabricación de medicamentos.
MX2020010384A MX392460B (es) 2014-04-09 2015-04-08 Proceso para la fabricacion de medicamentos

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010384A MX392460B (es) 2014-04-09 2015-04-08 Proceso para la fabricacion de medicamentos

Country Status (22)

Country Link
US (4) US20170022183A1 (enExample)
EP (2) EP3494971B1 (enExample)
JP (3) JP6723926B2 (enExample)
KR (3) KR20200038553A (enExample)
CN (3) CN112645927A (enExample)
AR (1) AR099989A1 (enExample)
AU (2) AU2015245743B2 (enExample)
BR (2) BR122020014933B8 (enExample)
CA (2) CA2945098C (enExample)
ES (1) ES2733495T3 (enExample)
HR (1) HRP20191306T1 (enExample)
IL (2) IL248205B (enExample)
MX (2) MX375638B (enExample)
MY (3) MY188526A (enExample)
NZ (1) NZ725450A (enExample)
PL (1) PL3129025T3 (enExample)
RU (1) RU2684102C2 (enExample)
SG (1) SG11201608421XA (enExample)
SI (1) SI3129025T1 (enExample)
TW (2) TWI678366B (enExample)
WO (1) WO2015154674A1 (enExample)
ZA (1) ZA201607066B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800282T1 (it) * 2012-03-01 2018-07-17 Genentech Inc Inibitori delle serina/treonina chinasi
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
UA120506C2 (uk) 2013-12-06 2019-12-26 Дженентек, Інк. Інгібітори серин/треонінкіназ
EP3494971B1 (en) 2014-04-09 2024-07-24 Genentech, Inc. Salts of erk inhibitors
CR20180316A (es) 2015-11-09 2018-10-05 Astrazeneca Ab Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
JP7530829B2 (ja) 2017-09-08 2024-08-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの診断及び治療方法
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
EP3546447A1 (en) * 2018-03-29 2019-10-02 Heidelberg Pharma GmbH Synthesis of (2s,3r,4r)-4,5-dihydroxyisoleucine and derivatives
WO2021110893A1 (en) * 2019-12-05 2021-06-10 Astrazeneca Ab Process and intermediates for the production of formula (i)
CN115710158A (zh) * 2021-08-23 2023-02-24 凯特立斯（深圳）科技有限公司 一种不对称催化制备替格瑞洛中间体的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
EP2001849B1 (en) * 2006-03-29 2014-11-26 F. Hoffmann-La Roche AG Pyridine and pyrimidine derivatives as mglur2 antagonists
JP2011503006A (ja) * 2007-11-06 2011-01-27 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性複素環アミン
SMT201800282T1 (it) * 2012-03-01 2018-07-17 Genentech Inc Inibitori delle serina/treonina chinasi
US9867667B2 (en) * 2014-02-27 2018-01-16 Canon Usa Inc. Placement apparatus
EP3494971B1 (en) 2014-04-09 2024-07-24 Genentech, Inc. Salts of erk inhibitors

Also Published As

Publication number Publication date
JP2020114817A (ja) 2020-07-30
EP3129025A1 (en) 2017-02-15
EP3494971C0 (en) 2024-07-24
JP2021167321A (ja) 2021-10-21
CN106659721B (zh) 2021-01-01
TWI762806B (zh) 2022-05-01
ZA201607066B (en) 2018-05-30
CN106659721A (zh) 2017-05-10
HRP20191306T1 (hr) 2019-10-18
RU2684102C2 (ru) 2019-04-04
EP3494971B1 (en) 2024-07-24
AU2015245743A1 (en) 2016-10-27
CN111777594B (zh) 2023-06-27
BR122020014933B1 (pt) 2022-11-29
CA3167641A1 (en) 2015-10-15
TWI678366B (zh) 2019-12-01
MX2020010384A (es) 2022-05-19
JP6974524B2 (ja) 2021-12-01
MX2016013162A (es) 2017-04-27
BR112016023391A2 (enExample) 2017-08-15
CN112645927A (zh) 2021-04-13
US20180134685A1 (en) 2018-05-17
ES2733495T3 (es) 2019-11-29
NZ725450A (en) 2022-08-26
BR112016023391B1 (pt) 2022-08-09
JP6723926B2 (ja) 2020-07-15
RU2016139286A3 (enExample) 2018-10-26
US20200190061A1 (en) 2020-06-18
MX392460B (es) 2025-03-24
US10611753B2 (en) 2020-04-07
IL268690A (en) 2019-10-31
MY188526A (en) 2021-12-18
AU2020220208B2 (en) 2022-03-17
EP3129025A4 (en) 2018-01-17
JP2017510620A (ja) 2017-04-13
RU2016139286A (ru) 2018-05-15
KR20230006043A (ko) 2023-01-10
US11098028B2 (en) 2021-08-24
KR102490955B1 (ko) 2023-01-19
BR122020014933B8 (pt) 2022-12-13
BR112016023391A8 (pt) 2018-04-17
MY196320A (en) 2023-03-24
US11066389B2 (en) 2021-07-20
EP3494971A1 (en) 2019-06-12
US20170022183A1 (en) 2017-01-26
CA2945098A1 (en) 2015-10-15
IL248205B (en) 2019-09-26
AU2015245743B2 (en) 2020-09-24
EP3129025B1 (en) 2019-05-15
CA2945098C (en) 2022-10-04
WO2015154674A1 (en) 2015-10-15
AR099989A1 (es) 2016-08-31
PL3129025T3 (pl) 2019-11-29
TW201945358A (zh) 2019-12-01
KR20200038553A (ko) 2020-04-13
SG11201608421XA (en) 2016-11-29
CN111777594A (zh) 2020-10-16
TW201620897A (zh) 2016-06-16
IL248205A0 (en) 2016-11-30
US20190367484A1 (en) 2019-12-05
AU2020220208A1 (en) 2020-09-10
KR20160133566A (ko) 2016-11-22
MY198371A (en) 2023-08-28
SI3129025T1 (sl) 2019-08-30

Similar Documents

Publication Publication Date Title
MX375638B (es) Proceso para la fabricación de medicamentos.
CL2019003154A1 (es) Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079)
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
EA201691799A1 (ru) Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201792021A1 (ru) Ингибитор jak
BR112016028773A2 (pt) processos para preparação de compostos antivirais
MX384201B (es) Proceso para la preparacion de treprostinil.
EA201690911A1 (ru) Соединения диметилбензойной кислоты
EA201791684A1 (ru) Селективные ингибиторы bace1
DK3233843T3 (da) Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
MX2021012440A (es) Farmacos precursores de oxabicicloheptanos.
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
MX2017004655A (es) Compuestos de hidroxil purinas y aplicaciones de estos.
MX384794B (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno.
CL2018002756A1 (es) Un proceso mejorado para la preparación de tartrato de butorfanol.
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
MX386134B (es) Proceso para la preparación de 5-fluoro-1h-pirazoles.
BR112019006963A2 (pt) método para preparar acetofenonas substituídas por ciclopropil
IN2014MU01192A (enExample)
IN2014MU00195A (enExample)
MX377314B (es) Sal de un derivado de cefalosporina, forma sólida cristalina del mismo y método para su producción.

Legal Events

Date Code Title Description
FG Grant or registration